We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tumor recurrence and tumor-related mortality in endometrial cancer: Analysis in 276 patients.
- Authors
A., Tejerizo-García; C., Álvarez-Conejo; L., Muñoz-Hernando; C., Guillén-Gámez; J. M., Seoane-Ruiz; C., Pérez-Sagaseta; J. S., Jiménez-López; Tejerizo-García, A; Álvarez-Conejo, C; Muñoz-Hernando, L; Guillén-Gámez, C; Seoane-Ruiz, J M; Pérez-Sagaseta, C; Jiménez-López, J S
- Abstract
<bold>Background: </bold>In this manuscript, we assessed tumor recurrence and tumor-related mortality in a clinical series of endometrial cancer patients.<bold>Materials and Methods: </bold>A retrospective evaluation of 276 patients (mean age 64 years) with histologically confirmed endometrial cancer treated at a single hospital in Madrid (Spain) was conducted. The median follow-up was estimated using the inverse Kaplan-Meier method.<bold>Results: </bold>Salient findings were endometrioid carcinoma (84.8% of cases), grade G1 (48.9%) and stages IB (35.1%) and IC (23.2%). Myometrial infiltration >50% was documented in 31.2% of cases and lymphovascular space invasion in 11.9%. After surgery, 52.5% of patients were classified into the low risk group, 21.4% into the intermediate risk group and 26.1% into the high risk group. Tumor recurrence occurred in 14.5% of patients, with an estimated median follow-up of 45 months (95% confidence interval (CI): 41.2-48.8), locoregional recurrence in 42.5% and distant recurrences in 57.5%. Furthermore, 40% of tumor recurrences developed during the first year after primary treatment and 90% over the first 3 years of follow-up. The tumor-related mortality rate was 15.9%. The estimated median follow-up was 46 months (95% CI: 43.0-49.0). Furthermore, 5.07% of death because of tumor developed during the first year after primary treatment and 13.77% over the first 3 years of follow-up.<bold>Conclusion: </bold>The rates of tumor-related death and tumor recurrence in endometrial cancer patients are low, with the highest percentages occurring within 3 years of primary treatment. Most of the recurrences occur outside the pelvis.
- Subjects
CANCER relapse; ONCOLOGIC surgery; TUMOR treatment; TREATMENT of endometrial cancer; CANCER treatment
- Publication
Indian Journal of Cancer, 2015, Vol 52, Issue 4, p682
- ISSN
0019-509X
- Publication type
journal article
- DOI
10.4103/0019-509X.178425